Trump-Era Funding Cuts and Hiring Freeze Stall UW Protein Design Startups Led by Nobel Laureate David Baker
The University of Washington's Institute for Protein Design, led by Nobel laureate David Baker, faces a hiring freeze and funding cuts under the Trump administration, stalling its promising protein design startups and reducing opportunities for graduate students and postdocs. Despite Nobel-driven interest and advances in AI-designed proteins, budget constraints threaten future innovation and company spinoffs.
University of Washington’s CoMotion Spins Out Seven New Startups Including Biotech and 3D Printing Ventures Since July 2023
Since July last year, the University of Washington's CoMotion has spun out seven new startups focused on innovations from biotech to 3D printing. These are part of over 110 active UW spinouts collectively employing 1,000+ people and raising $4.1 billion in the past five years.
AstraZeneca to Acquire UW Spinout Icosavax for Up to $1.1 Billion to Boost Respiratory Vaccine Development
AstraZeneca announced it will acquire Seattle-based biotech spinout Icosavax, founded at the University of Washington, for up to $1.1 billion to accelerate development of vaccines targeting respiratory viruses. Icosavax's shares surged over 40% after the deal, which values the company at a 43% premium and aims to advance its lead RSV and hMPV vaccine candidate.
See all 12 stories, episodes and videos about Neil King.
Seattle Flow is free for everyone.
- Claim and edit your profile
- Get alerts about you, your company, and anything else you care about
- Access the most comprehensive investor list in Seattle
- Join the conversation on news, podcasts, and events
Organizations
-
Institute for Protein Design Researcher · current
-
Institute for Protein Design, UW Medicine Associate Professor · current
-
Icosavax Scientific Co-founder · past